Urologix ®, Inc. (Nasdaq:ULGX) will host a conference call to present fiscal 2011 second quarter results on Tuesday, January 25, 2011 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-866-362-4831 and enter the Participant Passcode 10194653 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Stryker Warren, Jr., Chief Executive Officer, will host the call. Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until February 1, 2011 at 4:00 p.m. CT (5:00 p.m. ET). To listen to the replay, please dial 1-888-286-8010 and enter the Participant Passcode 13754728. The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents ( www.streetevents.com). About Urologix Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix’ products include the CoolWave® and Targis® control units and the CTC Advance™, Targis® and Prostaprobe® catheter families. All of Urologix’ products utilize Cooled ThermoTherapy™- targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.